As the burden of diabetes continues to rise globally, particularly in East Asian regions with high ALDH2*2 prevalence, restoring ALDH2 function represents a promising precision medicine strategy for mitigating DCM and related cardiometabolic complications. This evidence concerns the gene ALDH2 and familial dilated cardiomyopathy.